Atogepant is an oral medication approved for the preventive treatment of episodic migraine. It belongs to a class of drugs known as calcitonin gene-related peptide (CGRP) receptor antagonists [1].
How does atogepant work for migraine prevention?
Atogepant functions by blocking the activity of CGRP, a molecule that plays a significant role in migraine pathophysiology. CGRP is believed to contribute to migraine by causing vasodilation and transmitting pain signals [1][2]. By antagonizing the CGRP receptor, atogepant is thought to prevent CGRP from binding and initiating these migraine-associated processes, thereby reducing the frequency of migraine attacks [1].
What is the difference between atogepant and other CGRP treatments?
Atogepant is an oral CGRP receptor antagonist, distinguishing it from other CGRP-targeting therapies that are administered via injection, such as erenumab, fremanezumab, and galcanezumab, which are monoclonal antibodies that target the CGRP ligand or its receptor [3][4]. This oral formulation offers a different administration route for patients seeking preventive migraine treatment [1].
When does atogepant's patent protection expire?
The patent landscape for pharmaceuticals can be complex, involving multiple patents covering different aspects of a drug, including its formulation, manufacturing process, and method of use. Information on specific patent expiry dates for atogepant can be found through resources that track drug patents [5].
What clinical studies support atogepant's use?
The efficacy and safety of atogepant for the preventive treatment of episodic migraine were established in clinical trials. Key studies demonstrated a significant reduction in monthly migraine days compared to placebo. For instance, the ADVANCE trial showed that patients receiving atogepant experienced a greater reduction in mean monthly migraine days from baseline [1].
What are the potential side effects of atogepant?
Common side effects reported with atogepant include upper respiratory tract infections, nausea, and fatigue. Serious adverse events are infrequent, but as with any medication, patients should discuss potential risks and benefits with their healthcare provider [1].
How is atogepant prescribed?
Atogepant is typically prescribed as a once-daily oral tablet. The dosage may vary based on individual patient needs and physician recommendations [1].
Are there alternatives to atogepant for migraine prevention?
Beyond other CGRP inhibitors, various classes of oral preventive medications are available for migraine, including beta-blockers, anticonvulsants, and antidepressants, each with different mechanisms of action and side effect profiles. The choice of treatment often depends on the individual patient's medical history, comorbidities, and response to previous therapies [3][4].
---
1. Atogepant (Qulipta) [package insert].
2. Edvinsson L. CGRP and migraine: from bench to bedside. Rev Neurol (Paris). 2021 Aug-Sep;177(8):911-917.
3. Goadsby PJ, Lipton RB, Ferrari MD. Migraine-current understanding and treatment. N Engl J Med. 2002 Aug 29;346(9):707-14.
4. Silberstein SD. Preventive treatments for migraine. Continuum (Minneap Minn). 2015 Aug;21(4):975-91.
5. DrugPatentWatch.com.